Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increase in prevalence of myeloma
3.2.1.2 Development of novel treatment option for blood cancer
3.2.1.3 Surge in collaboration between pharmaceutical companies
3.2.2 Industry pitfalls & challenges
3.2.2.1 Adverse effects associated with lenalidomide
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter’s analysis
3.5.1 Supplier power
3.5.2 Buyer power
3.5.3 Threat of new entrants
3.5.4 Threat of substitutes
3.5.5 Industry rivalry
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive positioning matrix
4.4 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 5mg capsules
5.3 10mg capsules
5.4 15mg capsules
5.5 25mg capsules
Chapter 6 Market Estimates and Forecast, By Application, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Multiple myeloma (MM)
6.3 Myelodysplastic syndromes (MDS)
6.4 Other applications
Chapter 7 Market Estimates and Forecast, By End-User, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospitals
7.3 Cancer treatment centers
7.4 Research institutes
Chapter 8 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
8.1 Key trends, by region
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Accord Healthcare
9.2 Cipla
9.3 Deva Pharma
9.4 Dr. Reddy's Laboratories Ltd.
9.5 Glenmark Pharmaceuticals
9.6 Hetero
9.7 Hikma Pharmaceuticals
9.8 Lupin Limited
9.9 Sun Pharmaceutical Industries Ltd.
9.10 Teva Pharmaceutical Industries Ltd.
9.11 Torrent Pharmaceuticals Ltd.
9.12 Viatris Inc.
